Telehealth provider Raeliva has announced a rebrand and expansion of its online wellness platform, moving beyond its original GLP‑1 focus into a broader clinic model centered on peptides and longevity medicine.
From GLP‑1 to Peptide Care
Raeliva, formerly known as OnlineSemaglutide.org, built its initial patient base around semaglutide and tirzepatide for weight management. The company says it has supported more than 1,000 patients and now aims to provide care across multiple categories, including hormone health, hair health, and longevity. Treatments such as NAD+ and Sermorelin are part of the expanded offering, subject to clinical eligibility.
Tyler Cooper of Raeliva described the shift as a move away from being “just a peptide supplier” toward a full online clinic model. Patients begin with an intake reviewed by licensed providers, and prescriptions are issued only when appropriate. Fulfillment is handled through U.S.‑licensed compounding pharmacies, a distinction Raeliva emphasizes to separate its services from research‑grade peptides not intended for human use.
Transparency and Patient Education
The company highlighted transparency as a cornerstone of its new model, promising clear information on treatment options, pricing, and expectations before care begins. Raeliva says this approach is designed to build long‑term relationships with patients whose priorities may evolve from weight management to energy, recovery, or hormone health.
Global Context: Peptide Developments
Raeliva’s rebrand comes amid a surge of peptide‑related innovation worldwide. Recent developments include:
- GLP‑1 cardiovascular outcomes: The SELECT trial showed semaglutide reduces major adverse cardiovascular events in obese patients without diabetes.
- Dual and triple agonists: Drugs like tirzepatide and experimental retatrutide are pushing peptide therapeutics into new territory.
- AI‑driven peptide design: Machine learning platforms are accelerating discovery of stable, bioavailable peptide sequences.
- Oral peptide delivery: Advances in permeation enhancers are making oral formulations more viable, a long‑standing challenge in peptide medicine.
The Bigger Picture
By expanding beyond GLP‑1 care, Raeliva positions itself within a growing telehealth trend: integrating peptide therapies into mainstream wellness platforms. For patients, the promise is continuity of care across multiple health goals. For the industry, it signals peptides moving from niche research into everyday clinical practice — with oversight and transparency as critical differentiators.